Collaborative Arrangement, Annual License Fee

No definition available.

Name:	imdz_CollaborativeArrangementAnnualLicenseFee
Namespace Prefix:	imdz_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaborative Arrangement, Milestones Payable

+ References

No definition available.

+ Details

Name:	imdz_CollaborativeArrangementMilestonesPayable
Namespace Prefix:	imdz_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaborative Arrangement, Milestones Payable, Number of Payments Waived

+ References

No definition available.

+ Details

Name:	imdz_CollaborativeArrangementMilestonesPayableNumberofPaymentsWaived
Namespace Prefix:	imdz_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of License Agreements

+ References

No definition available.

+ Details

Name:	imdz_NumberofLicenseAgreements
Namespace Prefix:	imdz_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Revenue Recognition, Milestone Method, Milestones Receivable

+ References

No definition available.

+ Details

Name:	imdz_RevenueRecognitionMilestoneMethodMilestonesReceivable
Namespace Prefix:	imdz_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 28
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=68058744&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.

+ References

No definition available.

+ Details

Name:	us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.3(c)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 912
-SubTopic 310
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68054760&loc=d3e55302-109406

+ Details

Name:	us-gaap_UnbilledContractsReceivable
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

License and Collaboration Agreements - Narrative (Details)	1 Months Ended			12 Months Ended
	Oct. 31, 2016 USD ($) payment	Dec. 31, 2015 USD ($)	Nov. 30, 2015 USD ($)	Dec. 31, 2017 USD ($) license_agreement	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2009 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development				$ 43,670,000	$ 45,134,000	$ 33,087,000
TheraVectys SA \| Collaborative Arrangement \| Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential future milestone payments	$ 5,800,000
Number of milestone payments waived \| payment	2
GLAAS Discovery Platform \| Sanofi \| Collaborative Arrangement, Product
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone revenue recognized				0	7,000,000	1,000,000
Milestone receivables				160,000,000
GLAAS Discovery Platform \| Infectious Disease Research Institute \| Collaborative Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development			$ 250,000
GLA \| MedImmune LLC \| Collaborative Arrangement, Product
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone revenue recognized				0	0	2,500,000
GLA \| MedImmune LLC \| Collaborative Arrangement, Product \| Minimum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone receivables				62,900,000
GLA \| MedImmune LLC \| Collaborative Arrangement, Product \| Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone receivables				72,500,000
GLA \| Infectious Disease Research Institute \| Collaborative Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone revenue recognized				0	925,000	2,900,000
First GLAAS Discovery Platform Product \| Infectious Disease Research Institute \| Collaborative Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential future milestone payments				250,000
Subsequent GLAAS Discovery Platform Products \| Infectious Disease Research Institute \| Collaborative Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential future milestone payments				125,000
GLA/SLA Product \| Infectious Disease Research Institute \| Collaborative Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development		$ 2,300,000
GLA/SLA First Exclusive Product \| Infectious Disease Research Institute \| Collaborative Arrangement \| Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential future milestone payments				2,300,000
GLA/SLA Subsequent Exclusive Products \| Infectious Disease Research Institute \| Collaborative Arrangement \| Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential future milestone payments				1,300,000
GLA/SLA First Non-Exclusive Product \| Infectious Disease Research Institute \| Collaborative Arrangement \| Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential future milestone payments				1,300,000
GLA/SLA Subsequent Non-Exclusive Products \| Infectious Disease Research Institute \| Collaborative Arrangement \| Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential future milestone payments				625,000
Dendritic Cell-targeted Theraputic and Prophylactic Immunization Strategies \| California Institute of Technology \| Collaborative Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone revenue recognized				$ 100,000	0	0
Number of license agreements \| license_agreement				2
Annual license fee							$ 25,000
Dendritic Cell-targeted Theraputic and Prophylactic Immunization Strategies \| California Institute of Technology \| Collaborative Arrangement \| Common stock
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Value of common stock issued for license							$ 25,000
Dendritic Cell-targeted Theraputic and Prophylactic Immunization Strategies \| California Institute of Technology \| Collaborative Arrangement \| Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential future milestone payments				$ 1,500,000
Herpes Simplex Virus \| Sanofi Pasteur \| Collaborative Arrangement, Product
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Unbilled receivable				605,000	0
Unearned receivable				0	2,500,000
Herpes Simplex Virus \| Sanofi Pasteur \| Collaborative Arrangement, Product \| Collaboration Revenue
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone revenue recognized				$ 6,900,000	$ 4,600,000	$ 4,200,000